Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant
Amandine Le Bourgeois, Marianne Coste‐Burel, Thierry Guillaume, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 5
Open Access | Times Cited: 23

Showing 23 citing articles:

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 107
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
Nádia Emi Aikawa, Léonard de Vinci Kanda Kupa, Ana Cristina de Medeiros Ribeiro, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 1036-1043
Open Access | Times Cited: 40
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
Chenghao Ge, Kelei Du, Mingjie Luo, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 24
Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
Lorenzo Canti, Kevin K. Ariën, Isabelle Desombere, et al.
Cancer Cell (2022) Vol. 40, Iss. 4, pp. 335-337
Open Access | Times Cited: 20
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 158-158
Open Access | Times Cited: 17
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell–Depleted Stem Cell Transplantation
Ok-Kyong Chaekal, Alexandra Gomez-Arteaga, Zhengming Chen, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 9, pp. 618.e1-618.e10
Open Access | Times Cited: 16
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Jonathan Bordat, Sébastien Maury, Mathieu Leclerc
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis
Leyla Sharifi Aliabadi, Mojtaba Azari, Mohammad Reza Taherian, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies
Maryam Noori, Shadi Azizi, Farhan Abbasi Varaki, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109046-109046
Open Access | Times Cited: 14
Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis
Micah Rubin, Elizabeth Suelzer, Caden Ulschmid, et al.
Asian Pacific Journal of Cancer Prevention (2024) Vol. 25, Iss. 2, pp. 393-399
Open Access | Times Cited: 2
Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Israel Henig, Jonathan Isenberg, Dana Yehudai‐Ofir, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 775-775
Open Access | Times Cited: 6
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study
Maryam Barkhordar, Bahram Chahardouli, Alireza Biglari, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?
Ayman El‐Menyar, Naushad Ahmad Khan, Ahammed Mekkodathil, et al.
Medicine (2022) Vol. 101, Iss. 37, pp. e30609-e30609
Open Access | Times Cited: 8
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Tanaporn Meejun, Karan Srisurapanont, Kasama Manothummetha, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5624-5636
Open Access | Times Cited: 4
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
Béatrice Clémenceau, Amandine Le Bourgeois, Thierry Guillaume, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3010-3010
Open Access | Times Cited: 6
Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
Maxime Jullien, Marianne Coste‐Burel, Béatrice Clémenceau, et al.
eJHaem (2022) Vol. 3, Iss. 2, pp. 484-487
Open Access | Times Cited: 5
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation
Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 4
Serological response following anti-SARS-CoV-2 vaccination in hematopoietic stem cell transplantation patients depends upon time from transplant, type of transplant and “booster” dose
Immacolata Attolico, Francesco Tarantini, Paola Carluccio, et al.
Haematologica (2022) Vol. 107, Iss. 5, pp. 1218-1218
Open Access | Times Cited: 3
Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France
Valentin Letailleur, Amandine Le Bourgeois, Thierry Guillaume, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2247534-e2247534
Open Access | Times Cited: 3
Patients under medical conditions, immunogenicity and safety of covid-19 vaccines: a systematic review and meta-analysis
Attapon Cheepsattayakorn
Journal of Lung Pulmonary & Respiratory Research (2023) Vol. 10, Iss. 1, pp. 18-21
Open Access
Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study
Yasuo Mori, Naoyuki Uchida, Atsushi Wake, et al.
Vaccine (2023) Vol. 41, Iss. 47, pp. 6899-6903
Closed Access
Page 1

Scroll to top